MiMedx partners with Vaporox to co-market wound care products

MARIETTA, Ga. - MiMedx Group, Inc. (NASDAQ:MDXG), a wound care company with a market capitalization of $985 million and strong financial health according to InvestingPro data, and Vaporox, Inc. announced today a collaboration agreement to co-promote and co-market their respective wound care offerings. As part of the arrangement, MiMedx has made an investment in privately held Vaporox and secured certain exclusivity rights related to potential acquisition discussions.

Denver-based Vaporox has developed a patented Vaporous Hyperoxia Therapy (VHT) device for treating chronic wounds. The device, which has received FDA 510(k) clearance, delivers ultrasonic mist and concentrated oxygen in a single unit to treat nine types of wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers. MiMedx brings strong financials to this partnership, with InvestingPro analysis showing an impressive 82% gross profit margin and a healthy current ratio of 4.7, indicating robust operational efficiency and liquidity.

"We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox," said Joseph H. Capper, MiMedx Chief Executive Officer, according to the press release.

Alan Sage, Chief Executive Officer of Vaporox, stated that the partnership with MiMedx would help "accelerate our market penetration and create a synergistic offering."

The VHT technology has undergone three IRB clinical studies, each showing wound healing rates exceeding 80% at 20 weeks when combined with standard wound care, according to the companies. The therapy has also demonstrated promising results when used alongside MiMedx’s Advanced Wound Care products, such as EPIFIX.

MiMedx specializes in placental allografts for wound care applications, while Vaporox focuses on device-based treatment for chronic wounds.

Financial terms of the investment were not disclosed in the announcement.

This article is based on a press release statement from the companies.

In other recent news, MiMedx Group Inc. reported its first-quarter earnings for 2025, aligning with analyst expectations by achieving an earnings per share of $0.06. The company’s revenue slightly exceeded projections, reaching $88.2 million compared to the forecasted $86.36 million. This development follows a significant proposal from the Centers for Medicare and Medicaid Services (CMS) to change the reimbursement methodology for skin substitutes. CMS plans to implement a fixed price of $125.38 per square centimeter, replacing the current Average Sales Price method. Cantor Fitzgerald has maintained its Overweight rating on MiMedx, setting a price target of $11.00, in light of these proposed reimbursement changes. The announcement of the CMS proposal has notably impacted the wound-care industry, with MiMedx experiencing a 21% decline in share value. Despite this market reaction, the company’s financial performance remains consistent with expectations. Investors are advised to keep an eye on further developments regarding the CMS proposal and its potential effects on the sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.